PE20131343A1 - Derivados de acido benzoico - Google Patents

Derivados de acido benzoico

Info

Publication number
PE20131343A1
PE20131343A1 PE2013000320A PE2013000320A PE20131343A1 PE 20131343 A1 PE20131343 A1 PE 20131343A1 PE 2013000320 A PE2013000320 A PE 2013000320A PE 2013000320 A PE2013000320 A PE 2013000320A PE 20131343 A1 PE20131343 A1 PE 20131343A1
Authority
PE
Peru
Prior art keywords
methyl
benzoic acid
metoxyl
halogen
derivatives
Prior art date
Application number
PE2013000320A
Other languages
English (en)
Inventor
Mark Spyvee
Takashi Satoh
Jonathan Eric Carlson
Original Assignee
Eisai Randd Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Randd Man Co Ltd filed Critical Eisai Randd Man Co Ltd
Publication of PE20131343A1 publication Critical patent/PE20131343A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ACIDO BENZOICO DE FORMULA (I) DONDE UNO DE R1a Y R1b ES H Y EL OTRO ES METILO, O R1a Y R1b SE TOMAN JUNTOS PARA FORMAR UN CICLOPROPILO; R2 ES METILO O FLUOROMETILO; R3 ES METILO; R4 ES H, HALOGENO, FLUOROMETILO, METOXILO, ENTRE OTROS; R5 ES H, HALOGENO, METOXILO, ENTRE OTROS; R6 Y R7 SON CADA UNO H, HALOGENO, METILO O METOXILO; X ES O. SON COMPUESTOS PREFERIDOS LOS DE FORMULA (i), (ii), ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE
PE2013000320A 2010-09-21 2011-09-12 Derivados de acido benzoico PE20131343A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38478110P 2010-09-21 2010-09-21

Publications (1)

Publication Number Publication Date
PE20131343A1 true PE20131343A1 (es) 2013-11-18

Family

ID=44674894

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000320A PE20131343A1 (es) 2010-09-21 2011-09-12 Derivados de acido benzoico

Country Status (30)

Country Link
US (2) US8686018B2 (es)
EP (2) EP3061751A1 (es)
JP (1) JP5956448B2 (es)
KR (1) KR101911105B1 (es)
CN (1) CN103097358B (es)
AU (1) AU2011305872B2 (es)
BR (1) BR112013002484B1 (es)
CA (1) CA2806121C (es)
CL (1) CL2013000675A1 (es)
CY (1) CY1118680T1 (es)
DK (1) DK2619182T3 (es)
ES (1) ES2610185T3 (es)
HR (1) HRP20170042T1 (es)
HU (1) HUE031408T2 (es)
IL (1) IL224288A (es)
LT (1) LT2619182T (es)
ME (1) ME02575B (es)
MX (1) MX2013003162A (es)
MY (1) MY162146A (es)
NZ (1) NZ606629A (es)
PE (1) PE20131343A1 (es)
PL (1) PL2619182T3 (es)
PT (1) PT2619182T (es)
RS (1) RS55566B1 (es)
RU (1) RU2606510C2 (es)
SG (1) SG188188A1 (es)
SI (1) SI2619182T1 (es)
SM (1) SMT201700008B (es)
UA (1) UA113499C2 (es)
WO (1) WO2012039972A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
HUE039015T2 (hu) * 2013-06-12 2018-12-28 Kaken Pharma Co Ltd 4-Alkinil-imidazol-származék és ezt hatóanyagként tartalmazó gyógyszerkészítmény
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
MA39906A (fr) * 2014-05-23 2017-03-01 Eisai R&D Man Co Ltd Polythérapies pour le traitement du cancer
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
EP3325490B1 (en) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
EP3362454B1 (en) 2015-10-16 2021-12-08 Eisai R&D Management Co., Ltd. Ep4 antagonists
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
PT3625222T (pt) 2017-05-18 2021-10-07 Idorsia Pharmaceuticals Ltd Derivados de fenilo como moduladores do recetor de pge2
US11446298B2 (en) 2017-05-18 2022-09-20 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
SI3625228T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd Derivati pirimidina kot modulatorji receptorja PGE2
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
KR102650756B1 (ko) 2017-05-18 2024-03-22 이도르시아 파마슈티컬스 리미티드 N-치환된 인돌 유도체
CN108929281B (zh) * 2017-05-27 2021-12-24 华东师范大学 三氮唑类化合物及其合成方法和应用
CA3090485C (en) * 2018-02-05 2024-01-16 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases
WO2021175283A1 (zh) 2020-03-04 2021-09-10 湖北生物医药产业技术研究院有限公司 新型ep4拮抗剂的合成及其在癌症和炎症中的用途
CN114075140A (zh) * 2020-08-18 2022-02-22 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료
TW202227089A (zh) 2020-11-30 2022-07-16 大陸商杭州阿諾生物醫藥科技有限公司 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
CN116801879A (zh) * 2021-01-28 2023-09-22 深圳众格生物科技有限公司 吡唑酰胺衍生物及其制备方法和应用
WO2023030492A1 (zh) * 2021-09-03 2023-03-09 武汉人福创新药物研发中心有限公司 一种ep4拮抗剂化合物及其盐、多晶型和用途
CN115364222A (zh) * 2021-09-09 2022-11-22 首都医科大学附属北京地坛医院 Ep4受体抑制剂治疗肝纤维化的应用
WO2023122289A1 (en) 2021-12-23 2023-06-29 Eisai R&D Management Co., Ltd. Crystalline salt form of ep4 antagonist
TW202339723A (zh) * 2021-12-30 2023-10-16 大陸商杭州阿諾生物醫藥科技有限公司 一種固體藥物組合物
WO2024027599A1 (zh) * 2022-08-04 2024-02-08 杭州阿诺生物医药科技有限公司 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0421671A (ja) * 1990-05-16 1992-01-24 Mitsubishi Kasei Corp ４―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
TW591020B (en) 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
WO2004037212A2 (en) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
FR2847160A1 (fr) 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
ES2393950T3 (es) * 2003-06-26 2013-01-02 Novartis Ag Inhibidores de la quinasa P38 con base en heterociclos de 5 miembros
AU2004268839A1 (en) 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists
WO2005070889A1 (en) 2004-01-23 2005-08-04 E.I. Dupont De Nemours And Company Herbicidal amides
EP1756043B1 (en) * 2004-05-04 2009-07-01 RaQualia Pharma Inc Ortho substituted aryl or heteroaryl amide compounds
EP1756042B8 (en) 2004-05-04 2014-06-04 RaQualia Pharma Inc Substituted methyl aryl or heteroaryl amide compounds
EP1894919B1 (en) 2005-06-07 2012-03-28 Shionogi & Co., Ltd. Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
EP1891048A1 (en) * 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
RU2443689C2 (ru) 2005-11-21 2012-02-27 Сионоги Энд Ко., Лтд. ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЕ 1 ТИПА
CN101415687B (zh) * 2006-02-06 2012-02-08 大正制药株式会社 鞘氨醇-1-磷酸结合抑制物质
AU2007260529B2 (en) 2006-06-12 2012-04-19 Merck Canada Inc. Indoline amide derivatives as EP4 receptor ligands
WO2008017164A1 (en) 2006-08-11 2008-02-14 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
MX2009006474A (es) 2006-12-15 2009-06-26 Glaxo Group Ltd Derivados de benzamida como agonistas del receptor ep4.
JP5301469B2 (ja) 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
US7560936B1 (en) 2007-04-24 2009-07-14 Integrated Device Technology, Inc. Method and apparatus for ground bounce and power supply bounce detection
KR20100037101A (ko) 2007-06-15 2010-04-08 바스프 에스이 디플루오로메틸 치환된 피라졸 화합물의 제조 방법
JP5408434B2 (ja) 2007-07-03 2014-02-05 アステラス製薬株式会社 アミド化合物
NZ582057A (en) * 2007-07-19 2012-03-30 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
AR067744A1 (es) 2007-07-31 2009-10-21 Bayer Cropscience Sa Derivados fungicidas de (hetero) aril- metilen -n- cicloalquil carboxamida condensados de 6 elementos con n
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
JP5411927B2 (ja) * 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
AU2009247262B2 (en) 2008-05-14 2013-01-31 Astellas Pharma Inc. Amide compound
KR20110042092A (ko) 2008-08-01 2011-04-22 바이엘 크롭사이언스 아게 살진균제 ｎ-시클로알킬-ｎ-비페닐메틸-카르복사미드 유도체
CN102149384B (zh) * 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
JP2012503605A (ja) 2008-09-25 2012-02-09 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのベータ−カルボリンスルホニルウレア誘導体

Also Published As

Publication number Publication date
ME02575B (me) 2017-06-20
SI2619182T1 (sl) 2017-03-31
IL224288A (en) 2015-02-26
RS55566B1 (sr) 2017-05-31
BR112013002484A2 (pt) 2016-05-31
CN103097358A (zh) 2013-05-08
RU2606510C2 (ru) 2017-01-10
MY162146A (en) 2017-05-31
UA113499C2 (xx) 2017-02-10
HRP20170042T1 (hr) 2017-03-10
MX2013003162A (es) 2013-05-06
CA2806121A1 (en) 2012-03-29
EP3061751A1 (en) 2016-08-31
EP2619182B1 (en) 2016-11-09
JP2013538825A (ja) 2013-10-17
ES2610185T3 (es) 2017-04-26
US20130237578A1 (en) 2013-09-12
EP2619182A1 (en) 2013-07-31
BR112013002484B1 (pt) 2021-10-13
SMT201700008B (it) 2017-03-08
AU2011305872A1 (en) 2013-01-31
CL2013000675A1 (es) 2013-07-05
RU2013118209A (ru) 2014-10-27
JP5956448B2 (ja) 2016-07-27
SG188188A1 (en) 2013-04-30
KR101911105B1 (ko) 2018-10-23
DK2619182T3 (en) 2017-01-30
US8686018B2 (en) 2014-04-01
CA2806121C (en) 2018-10-09
PT2619182T (pt) 2017-01-17
CN103097358B (zh) 2015-04-08
WO2012039972A1 (en) 2012-03-29
LT2619182T (lt) 2017-01-25
US9000024B2 (en) 2015-04-07
CY1118680T1 (el) 2017-07-12
US20140155452A1 (en) 2014-06-05
NZ606629A (en) 2015-03-27
KR20130099008A (ko) 2013-09-05
AU2011305872B2 (en) 2015-03-26
PL2619182T3 (pl) 2017-03-31
HUE031408T2 (en) 2017-07-28

Similar Documents

Publication Publication Date Title
PE20131343A1 (es) Derivados de acido benzoico
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
UY34387A (es) Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización.
CL2012001627A1 (es) Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
PE20160654A1 (es) Compuestos de inhibidor de autotaxina
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
PE20141593A1 (es) Imidazopiridazinas sustituidas con amino
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
PE20141973A1 (es) Compuestos de heterociclilo como inhibidores de mek
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
PE20110196A1 (es) 5-alquinil-pirimidinas
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CL2015003357A1 (es) Derivados de nucleósidos 4'-fluoro-2'-metil sustituidos
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
CY1121163T1 (el) Ανταγωνιστες υποδοχεα σωματοστατινης υποτυπου 5 (sstr5)
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.

Legal Events

Date Code Title Description
FG Grant, registration